Turning Point Therapeutics is developing a pipeline of drugs designed for cancer patients. Turning Point’s approach is precision oncology - designing drug candidates so that they fit precisely where they’re supposed to. In this case, drugs that block a specific cell-signaling pathway that is driving tumor growth. To identify drugs, Turning Point is using their macrocycle platform that uses structure-based design to develop orally available proprietary targeted agents. Currently, Turning Point focuses on enhancing the ability of kinase inhibitors such that they are more potent and less susceptible to certain resistance mutations. Along with kinase inhibitors, Turning Point is advancing an antibody-drug conjugate to address gastrointestinal cancers.
Claim company profile to post jobs directly on this page and this website.